Medscape

Catumaxomab Effective in Treating Malignant Ascites

August 31, 2010 (Shenzhen, China) — Catumaxomab (Removab, Fresenius Biotech) is the first causal therapy against malignant ascites that has the approval of the European Commission. A phase 1/2 trial ...
ascopubs.org

Catumaxomab observational study to investigate efficacy and safety profile in clinical practice.

Phase II clinical trial to evaluate the safety of repeated cycles of intraperitoneal catumaxomab for the treatment of malignant ascites (SECIMAS). Background: The trifunctional anti-EpCAM/anti-CD3 ...
ascopubs.org

Effect of catumaxomab treatment in patients with peritoneal carcinomatosis and malignant ascites due to gastrointestinal cancers on survival.

Deferral of rectal surgery following a continued response to preoperative chemoradiotherapy (Watch and Wait) study: A phase II multicenter study in the United Kingdom. Background: In 2009 the ...
PharmiWeb

Pharmanovia Announces Launch of Korjuny (Catumaxomab) in Germany, a First-in-class Treatment for Malignant Ascites

Catumaxomab Is the Only Approved Drug Therapy for Malignant Ascites, a Rare and Debilitating Complication of Advanced-stage Cancer Launch Offers Prolonged Puncture-free Survival and Delayed ...
Nature

Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study

This is the first study investigating the safety and efficacy of the trifunctional antibody catumaxomab administered i.p. at the end of cytoreductive surgery and postoperatively prior to standard ...
The Globe and Mail

LINDIS BIOTECH AND PHARMANOVIA ANNOUNCE EUROPEAN MARKETING AUTHORISATION APPROVAL FOR CATUMAXOMAB, A FIRST-IN-CLASS TREATMENT FOR MALIGNANT ASCITES

CATUMAXOMAB BECOMES THE ONLY APPROVED DRUG THERAPY FOR MALIGNANT ASCITES, A RARE AND DEBILITATING COMPLICATION OF ADVANCED-STAGE CANCER UNDER A LICENSING AGREEMENT, LINDIS HAS GRANTED PHARMANOVIA THE ...